Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 105

Similar articles for PubMed (Select 24322336)

1.

Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.

Kajiura S, Hosokawa A, Yoshita H, Ueda Y, Ueda A, Mihara H, Ando T, Fujinami H, Nishikawa J, Ogawa K, Minemura M, Sugiyama T.

Am J Clin Oncol. 2013 Dec 7. [Epub ahead of print]

PMID:
24322336
2.

Dose escalation study of docetaxel and nedaplatin in patients with relapsed or refractory squamous cell carcinoma of the esophagus pretreated using cisplatin, 5-fluorouracil, and radiation.

Yoshioka T, Sakayori M, Kato S, Chiba N, Miyazaki S, Nemoto K, Shibata H, Shimodaira H, Ohtsuka K, Kakudo Y, Sakata Y, Ishioka C.

Int J Clin Oncol. 2006 Dec;11(6):454-60. Epub 2006 Dec 25.

PMID:
17180514
3.

A retrospective study of second-line chemotherapy for unresectable or recurrent squamous cell carcinoma of the esophagus refractory to chemotherapy with 5-fluorouracil plus platinum.

Yamazaki K, Hironaka S, Boku N, Yasui H, Fukutomi A, Yoshino T, Onozawa Y, Hasuike N, Inui T, Yamaguchi Y, Ono H.

Int J Clin Oncol. 2008 Apr;13(2):150-5. doi: 10.1007/s10147-007-0738-y. Epub 2008 May 8.

PMID:
18463960
4.

A single-institute phase I/II trial combining nedaplatin dose escalation with a fixed dose of docetaxel for induction chemotherapy of oral squamous cell carcinoma.

Miyazaki A, Kobayashi J, Yamamoto T, Kido Y, Takemura K, Abe M, Tomihara K, Dehari H, Nakamori K, Nagai I, Hiratsuka H.

Oral Oncol. 2008 May;44(5):471-6. Epub 2007 Sep 7.

PMID:
17826308
5.

A phase 1/11 study of second-line chemotherapy with fractionated docetaxel and nedaplatin for 5-FU/cisplatin-resistant esophageal squamous cell carcinoma.

Akutsu Y, Shuto K, Kono T, Uesato M, Hoshino I, Shiratori T, Miyazawa Y, Isozaki Y, Akanuma N, Matsubara H.

Hepatogastroenterology. 2012 Oct;59(119):2095-8.

PMID:
22328303
6.

Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.

Shim HJ, Cho SH, Hwang JE, Bae WK, Song SY, Cho SB, Lee WS, Joo YE, Na KJ, Chung IJ.

Am J Clin Oncol. 2010 Dec;33(6):624-8. doi: 10.1097/COC.0b013e3181bead92.

PMID:
20142726
7.

A phase II trial of docetaxel plus nedaplatin and 5-fluorouracil in treating advanced esophageal carcinoma.

Guo JF, Zhang B, Wu F, Wang B, Xing H, Zhu GY, Nie XY, Peng J.

Chin J Cancer. 2010 Mar;29(3):321-4.

8.

Dose-dense chemotherapy in metastatic gastric cancer with a modified docetaxel-cisplatin-5-fluorouracil regimen.

Tomasello G, Chiesa MD, Buti S, Brighenti M, Negri F, Rovere RK, Martinotti M, Buononato M, Brunelli A, Lazzarelli S, Donati G, Passalacqua R.

Tumori. 2010 Jan-Feb;96(1):48-53.

PMID:
20437857
9.

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial.

Roth AD, Maibach R, Fazio N, Sessa C, Stupp R, Morant R, Herrmann R, Borner MM, Goldhirsch A, de Braud F.

Ann Oncol. 2004 May;15(5):759-64.

10.

A pilot trial of docetaxel and nedaplatin in cisplatin-pretreated relapsed or refractory esophageal squamous cell cancer.

Nakajima Y, Suzuki T, Haruki S, Ogiya K, Kawada K, Nishikage T, Nagai K, Kawano T.

Hepatogastroenterology. 2008 Sep-Oct;55(86-87):1631-5.

PMID:
19102357
11.

A phase II study of docetaxel plus nedaplatin in patients with metastatic non-small-cell lung cancer.

Teramoto K, Asada Y, Ozaki Y, Suzumura Y, Nakano Y, Sawai S, Tezuka N, Inoue S, Fujino S.

Cancer Chemother Pharmacol. 2012 Oct;70(4):531-7. Epub 2012 Aug 5.

PMID:
22864949
12.

Phase I trial of combined chemotherapy with docetaxel, cisplatin, and 5-fluorouracil for patients with locally advanced squamous cell carcinoma of the head and neck.

Tsukuda M, Mikami Y, Tanigaki Y, Katori H, Horiuchi C, Ikeda Y, Taguchi T, Ono M, Yoshida T, Sakuma Y, Aikoh K.

Int J Clin Oncol. 2004 Jun;9(3):161-6.

PMID:
15221599
13.

Second-line combination chemotherapy with docetaxel and nedaplatin for Cisplatin-pretreated refractory metastatic/recurrent esophageal squamous cell carcinoma.

Jin J, Xu X, Wang F, Yan G, Liu J, Lu W, Li X, Tucker SJ, Zhong B, Cao Z, Wang D.

J Thorac Oncol. 2009 Aug;4(8):1017-21. doi: 10.1097/JTO.0b013e3181add9c7.

PMID:
19542899
14.

Evaluation of combined docetaxel and nedaplatin chemotherapy for recurrent esophageal cancer compared with conventional chemotherapy using cisplatin and 5-fluorouracil: a retrospective study.

Fujita Y, Hiramatsu M, Kawai M, Sumiyoshi K, Nishimura H, Tanigawa N.

Dis Esophagus. 2008;21(6):496-501. doi: 10.1111/j.1442-2050.2007.00806.x.

PMID:
18840134
15.

Combination second-line chemotherapy with gemcitabine and docetaxel for recurrent non-small-cell lung cancer after platinum-containing chemotherapy: a phase I/II trial.

Niho S, Kubota K, Goto K, Ohmatsu H, Matsumoto T, Kakinuma R, Nishiwaki Y.

Cancer Chemother Pharmacol. 2003 Jul;52(1):19-24. Epub 2003 Apr 24.

PMID:
12712259
16.

Docetaxel, nedaplatin, and S-1 (DGS) chemotherapy for advanced esophageal carcinoma: a phase I dose-escalation study.

Tanaka Y, Yoshida K, Osada S, Yamaguchi K, Takahashi T.

Anticancer Res. 2011 Dec;31(12):4589-97.

PMID:
22199335
17.

A phase I/II study of nedaplatin and 5-fluorouracil with concurrent radiotherapy in patients with esophageal cancer.

Sato Y, Takayama T, Sagawa T, Okamoto T, Miyanishi K, Sato T, Araki H, Iyama S, Abe S, Murase K, Takimoto R, Nagakura H, Hareyama M, Kato J, Niitsu Y.

Cancer Chemother Pharmacol. 2006 Nov;58(5):570-6. Epub 2006 Feb 4.

PMID:
16463059
18.

Prospective study of daily low-dose nedaplatin and continuous 5-fluorouracil infusion combined with radiation for the treatment of esophageal squamous cell carcinoma.

Osawa S, Furuta T, Sugimoto K, Kosugi T, Terai T, Yamade M, Takayanagi Y, Nishino M, Hamaya Y, Kodaira C, Yamada T, Iwaizumi M, Takagaki K, Yoshida K, Kanaoka S, Ikuma M.

BMC Cancer. 2009 Nov 22;9:408. doi: 10.1186/1471-2407-9-408.

19.

Biweekly docetaxel, cisplatin, and 5-fluorouracil (DCF) chemotherapy for advanced esophageal squamous cell carcinoma: a phase I dose-escalation study.

Tanaka Y, Yoshida K, Sanada Y, Osada S, Yamaguchi K, Takahashi T.

Cancer Chemother Pharmacol. 2010 Nov;66(6):1159-65. doi: 10.1007/s00280-010-1447-1. Epub 2010 Sep 28.

20.

Gemcitabine and docetaxel as second-line chemotherapy for patients with nonsmall cell lung carcinoma who fail prior paclitaxel plus platinum-based regimens.

Kosmas C, Tsavaris N, Vadiaka M, Stavroyianni N, Koutras A, Malamos N, Onyenadum A, Rokana S, Polyzos A, Kalofonos HP.

Cancer. 2001 Dec 1;92(11):2902-10.

PMID:
11753965
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk